- Home
- SWIM vs QURE Comparison
SWIM vs QURE Comparison
Compare SWIM & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$6.29
HOLD
Current Price
$22.40
Company Overview
Basic Information| Metric | SWIM | QURE |
|---|---|---|
| Founded | 1956 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 839.1M | 1.9B |
| IPO Year | 2021 | 2007 |
Fundamental Metrics
Financial Performance| Metric | SWIM | QURE |
|---|---|---|
| Price | $6.29 | $22.40 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | $6.25 | ★ $58.55 |
| AVG Volume (30 Days) | 676.9K | ★ 2.5M |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $533,235,000.00 | $15,751,000.00 |
| Revenue This Year | $8.96 | N/A |
| Revenue Next Year | $5.07 | $153.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.12 | N/A |
| 52 Week Low | $4.56 | $7.76 |
| 52 Week High | $8.46 | $71.50 |
Technical Indicators
Market Signals| Indicator | SWIM | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 41.84 | 38.06 |
| Support Level | $6.18 | $22.15 |
| Resistance Level | $6.58 | $24.10 |
| Average True Range (ATR) | 0.22 | 1.51 |
| MACD | 0.01 | 0.51 |
| Stochastic Oscillator | 23.85 | 42.09 |
Price Performance
Historical Comparison SWIM
QURE
About SWIM Latham Group Inc.
Latham Group Inc is a designer, manufacturer, and marketer of in-ground residential swimming pools, liners, and covers in North America, Australia, and New Zealand. It derives a majority of its revenue from the United States.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.